New Trend Emerging in Borderline Treatment

By Boschert, Sherry | Clinical Psychiatry News, May 2011 | Go to article overview

New Trend Emerging in Borderline Treatment


Boschert, Sherry, Clinical Psychiatry News


SAN FRANCISCO -- Trials of drug therapy for borderline personality disorder have produced conflicting results and controversy, but a new trend is emerging: targeting medications to syndromes within the diagnosis.

Two or three recent meta-analyses of studies provide some support for this strategy, Dr. S. Charles Schulz said at the meeting, where he led an interest group discussion on drug therapy for borderline personality disorder.

"For the impulsive-aggressive borderline patients, the mood-stabilizing anticonvulsants have a very significant effect. For anger and cognitive or perceptual disturbance, the atypical antipsychotics are pretty good. For some depressed patients" with borderline personality disorder, the selective serotonin reuptake inhibitors (SSRIs) "can be useful," though they have a small effect in these patients, said Dr. Schulz, chair of psychiatry at the University of Minnesota, Minneapolis.

As a result, in the last 4 years or so, clinicians are thinking more in terms of targeting medications to subsets of patients rather than drug therapy for borderline personality disorder as a whole, he said. "That's emerging" and is a strategy worth testing in prospective trials, Dr. Schulz said. The scant data in the meta-analyses are "nowhere near enough to fully support what these meta-analyses" suggest, he added.

No medications have been approved by the Food and Drug Administration to treat borderline personality disorder.

Research also is needed to build on preliminary studies of combining drug therapy with psychosocial therapy for borderline personality disorder, he said. One preliminary study found that people with borderline personality disorder who were randomized to dialectical behavior therapy (DBT) plus the atypical antipsychotic olanzapine showed significantly more improvement than did patients who got DBT plus placebo. "The strongest impact was on decreased danger," he said.

Studies of combining medications and psychosocial therapies are much more common for other psychiatric diagnoses than for borderline personality disorder, Dr. Schulz noted. "I would really like for us to step it up and mirror some of the other studies done for schizophrenia and bipolar disorder," he said.

He believes the National Institute of Mental Health should better fund large studies of drug therapy for borderline personality disorder, as it has for other diagnoses.

"I feel pretty passionately about this," Dr. Schulz said in an interview after the group discussion. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • A full archive of books and articles related to this one
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

New Trend Emerging in Borderline Treatment
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

    Already a member? Log in now.